Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.79−0.14 (-7.25%)
Close on Nov 12, 2026Market cap $2.92MP/E –Yield –
Ernexa Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ernexa Therapeutics's price to sales ratio was 456.9× on Apr 30, 2025, against 176.1× a year earlier. Over the last 4 years it ranged from 28.7× to 456.9×, with a median of 74.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 456.9× | +423.3 |
| 2019 | Oct 31, 2019 | 33.6× | −24.4 |
| 2018 | Jan 31, 2018 | 58.1× | +14.6 |
| 2017 | Dec 29, 2017 | 43.4× | −132.7 |
| 2014 | Jan 31, 2014 | 176.1× | +0.0 |
| 2013 | Dec 31, 2013 | 176.1× | +120.7 |
| 2012 | Dec 31, 2012 | 55.4× | −1.4 |
| 2011 | Dec 30, 2011 | 56.8× | – |
See a number that looks wrong?